Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Prostatic Neoplasms
  • Retinoblastoma Protein

abstract

  • We conclude that p16 cytoplasmic expression can be used as a predictor of outcome in conservatively treated prostate cancer. Rb and p21 show no independent association with outcome and therefore further research is not warranted.

publication date

  • October 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3109/00313025.2010.508788

PubMed ID

  • 20854069

Additional Document Info

start page

  • 519

end page

  • 23

volume

  • 42

number

  • 6